PB006: A Natalizumab Biosimilar

• Published in: Clinical drug investigation Vol. 44; no. 5; pp. 367 - 370
• Main Author: Shirley, Matt
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2024; Springer Nature B.V
• Subjects: Adis Biosimilar Brief; Antibodies; Biological products; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - pharmacokinetics; Biosimilar Pharmaceuticals - therapeutic use; Cell adhesion & migration; Drug dosages; Humans; Internal Medicine; Magnetic resonance imaging; Medicine; Medicine & Public Health; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Natalizumab - adverse effects; Natalizumab - therapeutic use; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy

PB006 (Tyruko ® ) is the first biosimilar of the reference monoclonal anti-α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple scl...